Document is current

Article History

Received: 31 May 2023

Accepted: 13 July 2023

First Online: 18 July 2023

Declarations

:

: The study was approved by the ethics committee of the Medical University Vienna (ethical approval number: 2216/2020). Written informed consent was obtained from all patients. This study adheres to the reporting guidelines outlined within the 'Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement.

: Not applicable.

: Nik Krajnc: has participated in meetings sponsored by, received speaker honoraria or travel funding from BMS/Celgene, Janssen-Cilag, Merck, Novartis, Roche and Sanofi-Genzyme and held a grant for a Multiple Sclerosis Clinical Training Fellowship Programme from the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).Bianca Itariu: declares no conflict of interest relevant to this study.Stefan Macher: declares no conflict of interest relevant to this study.Wolfgang Marik: declares no conflict of interest relevant to this study.Jürgen Harreiter: has participated in meetings sponsored by, received speaker/consultancy honoraria or travel funding from Novo Nordisk, Sanofi, Novartis, Eli Lilly, Boehringer-Ingelheim. He has received unrestricted research grants from Bayer and Astra Zeneca.Martin Michl: declares no conflict of interest relevant to this study.Klaus Novak: declares no conflict of interest relevant to this study.Christian Wöber: has received honoraria consultancy/speaking from Apomedica, Curelator, Eli Lilly, Grünenthal, Hermes, Lundbeck, Novartis, Pfizer, Ratiopharm/Teva, and Stada.Berthold Pemp: declares no conflict of interest relevant to this study.Gabriel Bsteh: has participated in meetings sponsored by, received speaker honoraria or travel funding from Biogen, Celgene/BMS, Lilly, Merck, Novartis, Roche, Sanofi-Genzyme and Teva, and received honoraria for consulting Biogen, Celgene/BMS, Novartis, Roche, Sanofi-Genzyme and Teva. He has received unrestricted research grants from Celgene/BMS and Novartis.